Prostate adenocarcinoma and human immunodeficiency virus: Report of three cases and review of the literature

Clinical Genitourinary Cancer

Volumn 5, Issue 1, 2006, Pages 85-88

  O'Connor, John K ^a,b   Nedzi, Lucien A ^a,b   Zakris, Ellen L ^a,b  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; CD4; Prostate specific antigen; Radiation therapy

Indexed keywords

ANTIANDROGEN; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER RISK; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL RECTAL EXAMINATION; DISEASE DURATION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MALE; MEDICAL LITERATURE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME; ADENOCARCINOMA; MIDDLE AGED; PROSTATE TUMOR; REVIEW;

ADENOCARCINOMA; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 33749072728     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.023     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention (CDC). Epidemiology of HIV/ AIDS - United States, 1981-2005. MMWR Morb Mortal Wkly Rep 2006; 55:589-592.
2. The Joint United Nations Programme on HIV/AIDS, UNAIDS. AIDS Epidemic Update 2005. Avaliable at: http://www.unaids.org/epi/2005/doc/docs/ PR_EpiUpdate_Nov05_en.pdf. Accessed April 27, 2005.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733.
4. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out-patient Study Investigators. N Engl J Med 1998; 338:853-860.
5. Berzofsky JA, Ahlers JD, Janik J, et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 2004; 114:450-462.
6. HIV/AIDS Surveillance Report. Vol 13, No 2. Atlanta: Centers for Disease Control and Prevention (CDC); 2001.
7. Devita VT, Hellman S, Rosenberg SA, et al. CANCER Principles and Practice of Oncology. 7th ed. Lippincott Williams & Wilkins; 2005.
8. Abeloff MD, ed. Clinical Oncology. 3rd ed. Churchill-Livingstone; 2004.
9. Crum NF, Spencer CR, Amling CL. Prostate carcinoma among men with human immunodeficiency virus infection. Cancer 2004; 101:294-299.
10. Levinson A, Nagler EA, Lowe FC. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology 2005; 65:91-94.
11. Quatan N, Nair S, Harrowes F, et al. Should HIV patients be considered a high risk group for the development of prostate cancer? Ann R Coll Surg Engl 2005; 87:437-438.
12. Manfredi R, Fulgaro C, Sabbatani S, et al. Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features open questions for urologists, oncologists, and infectious disease specialists. Cancer Detect Prev 2006; 30:20-23.
13. Schwartz JD, Prince D. Prostate cancer in HIV infection. AIDS 1996; 10:797-798.
14. Staiman V, Lowe FC. Prostatic disease in HIV infected patients. Infect Urol 1996; 9:42-47.
15. Furco A, Bani-Sadr F, Guymar S, et al. Metastatic prostate cancer of the prostate in a young 40 year-old HIV-infected male patient. Presse Med 2003; 32:930-931.
16. Gastaut JL, Cesar P, Sobel A, et al. Encephalopathie progressive chez un homme de 82 ans ayant une serologi HIV positive et an cancer de la prostate. Rev Neurol 1991; 147:251-257.
17. Pauker SG. Prostatic cancer in a patient with asymptomatic HIV infection: are some lives more equal than others? Med Decis Making 1988; 8:132-144.
18. Nelson WG, De Marzo AM, Issacs WB. Mechanisms of disease: prostate cancer. N Eng J Med 2003; 349:366-381.
19. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004; 171:S36-S40.
20. De Marzo AM, Marchi VL, Epstein JL, et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155:1985-1992.
21. Smith DM, Kingery JD, Wong JK, et al. The prostate as a reservoir for HIV-1. AIDS 2004; 18:1600-1602.
22. Michalski JM, Purdy JA, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000; 46:391.
23. Kim JH, Sarani B, Orkin BA, et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum 2001; 44:1496-1502.
24. Place RJ, Gregorcyk SG, Huber PJ, et al. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum 2001; 44:506-512.
25. Hoffman R, Welton ML, Klencke B, et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 1999; 44:127-131.